Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells

Journal of Clinical Biochemistry and Nutrition

Volumn 45, Issue 2, 2009, Pages 163-170

  Wang, Quanxin ^a   Takei, Yoshiyuki ^b   Kobayashi, Osamu ^a   Osada, Taro ^a   Watanabe, Sumio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colon cancer cells; Cyclooxygenase 2; Cytotoxic T lymphocytes; FasL; TRAIL

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FAS LIGAND; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER INHIBITION; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 70350331297     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.09-21     Document Type: Article

References (36)

1. DuBois, R.N., Tsujii, M., Bishop, P., Awad, J.A., Makita, K., and Lanahan, A.: Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal cells. Am. J. Physiol., 266, G822-G827, 1996.
2. Eberhart, C.E. and DuBois, R.N.: Eicosanoids and the gastrointestinal tract. Gastroenterology, 109, 285-301, 1995.
3. Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W., and Herschman, H.R.: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cell encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem., 266, 12866-12872, 1991.
4. Mutoh, H., Hayakawa, H., Sakamoto, H., and Sugano, K.: Homobox. protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB. J. Gastroenterol., 42, 719-729, 2007. (Pubitemid 47456759)
5. Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S., and DuBois, R.N.: Up-regulation of cyclooxygenase 2 gene expression in human colo-rectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-1188, 1994. (Pubitemid 24294584)
6. Elder, D.J.E., Baker, J.A., Banu, N.A.E., Moorghen, M., and Paraskeva, C.: Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J. Pathol., 198, 428-434, 2002. (Pubitemid 35446995)
7. Sheehan, K.M., Sheahan, K., O'Donoghue, D.P., MacSweeney, F., Conroy, R.M., Fitzgerald, D.J., and Murray, F.E.: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA, 282, 1254-1257, 1999. (Pubitemid 29468497)
8. Sinicrope, F.A., Half, E., Morris, J.S., Lynch, P.M., Morrow, J.D., Levin, B., Hawk, E.T., Cohen, D.S., Ayers, G.D., Stephens, L.C., and Familial Adenomatous Polyposis Study Group: Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol. Biomarkers Prev., 13, 920-927, 2004.
9. Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon, G.B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L.K., and Levin, B.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familiar adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952, 2000.
10. Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J.M., Evans, J.F., and Taketo, M.M.: Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2(COX2). Cell, 87, 803-809, 1996.
11. Kawamori, T., Rao, C.V., Seibert, K., and Reddy, B.S.: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409-412, 1998. (Pubitemid 28087398)
12. Jacoby, R.F., Seibert, K., Cole, C.E., Kelloff, G., and Lubet, R.A.: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res., 60, 5040-5044, 2000. (Pubitemid 30739757)
13. Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., Taketo, M.M., and Evans, J.F.: Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 61, 1733-1740, 2001. (Pubitemid 34292612)
14. Tomozawa, S., Nagawa, H., Tsuno, N., Hatano, K., Osada, T., Kitayama, J., Sunami, E., Nita, M.E., Ishihara, S., Yano, H., Tsuruo, T., Shibata, Y., and Muto, T.: Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer, 81, 1274-1279, 1999.
15. Li, M., Wu, X., and Xu, X.C.: Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin. Cancer Res., 7, 1010-1016, 2001.
16. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R.N.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93, 705-716, 1998. (Pubitemid 28257578)
17. Masferrer, J.L., Leahy, K.M., Koki, A.T., Zweifel, B.S., Settle, S.L., Woerner, B.M., Edwards, D.A., Flickinger, A.G., Moore, R.J., and Seibert, K.: Antiangiogenic and antitumor activities of cyciooxygenase-2 inhibitors. Cancer Res., 60, 1306-1311, 2000.
18. Holash, J., Maisonpierre, P.C., Compton, D., Boland, P., Alexander, C.R., Zagzag, D., Yancopoulos, G.D., and Wiegand, S.J.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 284, 1994-1998, 1999. (Pubitemid 29309448)
19. Tsujii, M., Kawano, S., and DuBois, R.N.: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A., 94, 3336-3340, 1997.
20. Ropponen, K.M., Eskelinen, M.J., Lipponen, P.K., Alhava, E., and Kosma, V.M.: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol., 182, 318-324, 1997. (Pubitemid 27285785)
21. Seki, N., Brooks, A.D., Carter, C.R., Back, T.C., Parsoneault, E.M., Smyth, M.J., Wiltrout, R.H., and Sayers, T.J.: Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol., 168, 3484-3492, 2002.
22. Nakayama, M., Kayagaki, N., Yamaguchi, N., Okumura, K., and Yagita, H.: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J. Exp. Med., 192, 1373-1380, 2000.
23. Farinas, M.C., Rodriguez-Valverde, V., Zarrabeitia, M.T., Parra-Blanco, J.A., and Sanz-Ortiz, J.: Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer. Cancer, 68, 1279-1284, 1991.
24. Yoshino, I., Yano, T., Yoshikai, Y., Murata, M., Sugimachi, K., Kimura, G., and Nomoto, K.: Oligoclonal T lymphocytes infiltrating human lung cancer tissues. Int. J. Cancer, 47, 654-658, 1991.
25. Lang, S., Lauffer, L., Clausen, C., Lohr, I., Schmitt, B., Holzel, D., Wollenberg, B., Gires, O., Kastenbauer, E., and Zeidler, R.: Impaired monocyte function in cancer patients: Restoration with a cyclooxygenase-2 inhibitor. FASEB J., 17, 286-288, 2003.
26. Brunda, M.J., Herberman, R.B., and Holden, H.T.: Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol., 124, 2682-2687, 1980. (Pubitemid 10116039)
27. Kubota, Y., Sunouchi, K., Ono, M., Sawada, T., and Muto, T.: Local immunity and metastasis of colorectal carcinoma. Dis. Colon Rectum, 35, 645-650, 1992.
28. Goodwin, J.S. and Ceuppens, J.: Regulation of the immune response by prostaglandins. J. Clin. Immunol., 3, 295-315, 1983.
29. O'Connell, J., O'Sullivan, G.C., Collins, J.K., and Shanahan, F.: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184, 1075-1082, 1996.
30. Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G., Ludwig, H., Geley, S., Kofier, R., and Greil, R.: Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90, 12-20, 1997. (Pubitemid 27276541)
31. Gastman, B.R., Atarshi, Y., Reichert, T.E., Saito, T., Balkir, L., Rabinowich, H., and Whiteside, T.L.: Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res., 59, 5356-5364, 1999. (Pubitemid 29504005)
32. Bennett, M.W., O'Connell, J., O'Sullivan, G.C., Brady, C., Roche, D., Collins, J.K., and Shanahan, F.: The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immuno., 160, 5669-5675, 1998. (Pubitemid 28267863)
33. Ryan, A.E., Shanahan, F., O'Connell, J., and Houston, A.M.: Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res., 65, 9817-9823, 2005.
34. Jones, M.K., Wang, H., Peskar, B.M., Levin, E., Itani, R.M., Sarfeh, I.J., and Tarnawski, A.S.: Inhibition of angiogenesis by non steroidal anti-inflammatory drugs:insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 5, 1418-1423, 1999.
35. Uefuji, K., Ichikura, T., Shinomiya, N., and Mochizuki, H.: Induction of apoptosis JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res., 20, 4279-4284, 2000. (Pubitemid 32141773)
36. Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., Stringaro, A., Molinari, A., Arancia, G., Gentile, M., Parmiani, G., and Fais, S.: Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med., 195, 1303-1316, 2002.